Article citationsMore>>

C. Buske, E. Hoster and M. Dreyling, “German LowGrade Lymphoma Study Group. The Addition of Rituximab to Front-Line Therapy with CHOP (R-CHOP) Results in a Higher Response Rate and Longer Time to Treatment Failure in Patients with Lymphoplasmacytic Lymphoma: Results of a Randomized Trial of the German Low-Grade Lymphoma Study Group (GLSG),” Leukemia, Vol. 23, No. 1, 2009, pp. 153-161. doi:10.1038/leu.2008.261

has been cited by the following article:

SCIRP Newsletter
Copyright © 2006-2026 Scientific Research Publishing Inc. All Rights Reserved.
Top